← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Azitra, Inc. (AZTR) 10-Year Financial Performance & Capital Metrics

AZTR • • Industrial / General
HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune
AboutAzitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.Show more
  • Revenue $8M +993.3%
  • EBITDA -$10.98B -156265.8%
  • Net Income -$9M +20.5%
  • EPS (Diluted) -0.36 +91.5%
  • Gross Margin 100%
  • EBITDA Margin -146462.56% -14202.3%
  • Operating Margin -146468.53% -13385.9%
  • Net Margin -119.57% +92.7%
  • ROE -208.27% +46.2%
  • ROIC -445079.83% -159448.3%
  • Debt/Equity 0.10 -67.9%
  • Interest Coverage -903383.22 -2033587.9%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Trading at only 0.0x book value
  • ✓Efficient asset utilization: 1.0x turnover

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 4 (bottom 4%)
  • ✗Shares diluted 100.0% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y308.53%
TTM-100%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-23.11%

EPS CAGR

10Y-
5Y-
3Y-
TTM3.66%

ROCE

10Y Avg-57949.13%
5Y Avg-57949.13%
3Y Avg-77231.33%
Latest-231382.14%

Peer Comparison

Dermatology & Autoimmune
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
AUPHAurinia Pharmaceuticals Inc.1.96B14.87378.3733.97%29.28%21.28%2.25%0.21
ARGXargenx SE50.33B813.2463.6378.6%23.34%15.14%0.01
INVAInnoviva, Inc.1.48B19.7654.8915.54%32.78%12.61%12.75%0.65
GLPGGalapagos N.V.2.24B34.0330.3814.99%-151.94%-15.16%0.00
PTGXProtagonist Therapeutics, Inc.5.3B84.7520.046.24%21.94%7.11%3.45%0.02
ALMSAlumis Inc. Common Stock2.84B24.17-2.33-11.08%-63.71%0.12
PHATPhathom Pharmaceuticals, Inc.1.17B14.98-2.8380.01%-186.53%
ORKAOruka Therapeutics, Inc.1.57B32.50-6.51-22.44%0.00

Profit & Loss

Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+110K284K686K7.5M
Revenue Growth %-1.58%1.42%9.93%
Cost of Goods Sold+0000
COGS % of Revenue----
Gross Profit+110K284K686K7.5M
Gross Margin %1%1%1%1%
Gross Profit Growth %-1.58%1.42%9.93%
Operating Expenses+9.33M9.74M8.14M10.99B
OpEx % of Revenue84.83%34.29%11.86%1465.69%
Selling, General & Admin3.95M3.64M4.49M6.27B
SG&A % of Revenue35.92%12.82%6.55%835.9%
Research & Development5.38M6.1M3.64M4.72B
R&D % of Revenue48.91%21.47%5.31%629.78%
Other Operating Expenses0000
Operating Income+-9.22M-9.45M-7.45M-10.99B
Operating Margin %-83.83%-33.29%-10.86%-1464.69%
Operating Income Growth %--0.03%0.21%-1473.41%
EBITDA+-9.14M-9.05M-7.02M-10.98B
EBITDA Margin %-83.06%-31.86%-10.24%-1464.63%
EBITDA Growth %-0.01%0.22%-1562.66%
D&A (Non-Cash Add-back)84.77K405.98K425.55K448.24K
EBIT-8.87M-10.43M-11.1M-8.95M
Net Interest Income+-58.21K-247.07K-166.15K110.39K
Interest Income8.76K4.82K1.58K122.55K
Interest Expense66.97K251.89K167.73K12.16K
Other Income/Expense281.78K-1.23M-3.82M10.98B
Pretax Income+-8.94M-10.68M-11.27M-8.96M
Pretax Margin %-81.27%-37.61%-16.42%-1.19%
Income Tax+0017.31K9.03K
Effective Tax Rate %1%1%1%1%
Net Income+-8.94M-10.68M-11.28M-8.97M
Net Margin %-81.27%-37.61%-16.45%-1.2%
Net Income Growth %--0.19%-0.06%0.21%
Net Income (Continuing)-8.94M-10.68M-11.28M-8.97M
Discontinued Operations0000
Minority Interest0000
EPS (Diluted)+-3.33-3.98-4.20-0.36
EPS Growth %--0.19%-0.06%0.92%
EPS (Basic)-3.33-3.98-7.34-0.36
Diluted Shares Outstanding60.49K60.49K34.51K567.57K
Basic Shares Outstanding60.49K60.49K34.51K567.57K
Dividend Payout Ratio----

Balance Sheet

Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+8.49M4.14M2.54M5.23M
Cash & Short-Term Investments8.04M3.49M1.8M4.55M
Cash Only8.04M3.49M1.8M4.55M
Short-Term Investments0000
Accounts Receivable334.18K266.21K223.47K101.9K
Days Sales Outstanding1.11K342.13118.94.96
Inventory0000
Days Inventory Outstanding----
Other Current Assets0216.89K67.86K4.11K
Total Non-Current Assets+1.71M3.03M2.58M2.13M
Property, Plant & Equipment946.68K1.96M1.58M1.21M
Fixed Asset Turnover0.12x0.14x0.43x6.22x
Goodwill0000
Intangible Assets97.69K219.57K210.88K246.42K
Long-Term Investments0000
Other Non-Current Assets668.23K848.34K789.99K678.22K
Total Assets+10.2M7.17M5.12M7.36M
Asset Turnover0.01x0.04x0.13x1.02x
Asset Growth %--0.3%-0.29%0.44%
Total Current Liabilities+1.21M2.22M1.6M1.38M
Accounts Payable717.8K784.69K897.27K490.25K
Days Payables Outstanding----
Short-Term Debt0000
Deferred Revenue (Current)15K156K00
Other Current Liabilities43.47K27.08K145.04K32.97K
Current Ratio7.02x1.86x1.58x3.80x
Quick Ratio7.02x1.86x1.58x3.80x
Cash Conversion Cycle----
Total Non-Current Liabilities+34.76M41.21M599.14K284.65K
Long-Term Debt992.02K6.6M00
Capital Lease Obligations0840.9K563.69K284.27K
Deferred Tax Liabilities0000
Other Non-Current Liabilities33.77M33.76M35.45K381
Total Liabilities35.97M43.43M2.2M1.66M
Total Debt+992.02K7.73M885.95K555.51K
Net Debt-7.05M4.24M-910.04K-4M
Debt / Equity--0.30x0.10x
Debt / EBITDA----
Net Debt / EBITDA----
Interest Coverage-137.70x-37.53x-44.42x-903383.22x
Total Equity+-25.77M-36.26M2.91M5.7M
Equity Growth %--0.41%1.08%0.96%
Book Value per Share-425.93-599.4184.4010.04
Total Shareholders' Equity-25.77M-36.26M2.91M5.7M
Common Stock1041041.21K763
Retained Earnings-26.63M-37.31M-48.6M-57.57M
Treasury Stock0000
Accumulated OCI0000
Minority Interest0000

Cash Flow

Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-8.07M-8.35M-7.36M-10.18M
Operating CF Margin %-73.34%-29.4%-10.73%-1.36%
Operating CF Growth %--0.03%0.12%-0.38%
Net Income-8.94M-10.68M-11.28M-8.97M
Depreciation & Amortization84.77K405.98K425.55K448.24K
Stock-Based Compensation306.06K184.47K151.5K245.05K
Deferred Taxes0000
Other Non-Cash Items-164.86K1.43M4.1M-1.47M
Working Capital Changes646.35K310.76K-753.43K-441.72K
Change in Receivables194.17K66.67K42.73K133.15K
Change in Inventory0000
Change in Payables282.98K420.75K-68.68K-140.53K
Cash from Investing+-652.27K-336.76K-318.26K-379.25K
Capital Expenditures-446.14K-33.1K-26.54K-8.57K
CapEx % of Revenue4.06%0.12%0.04%0%
Acquisitions----
Investments----
Other Investing-206.14K-303.66K-291.71K-370.68K
Cash from Financing+992.86K4.13M5.98M13.32M
Debt Issued (Net)----
Equity Issued (Net)----
Dividends Paid0000
Share Repurchases----
Other Financing8.47K-215.38K0-18.38K
Net Change in Cash----
Free Cash Flow+-8.72M-8.69M-7.68M-10.56M
FCF Margin %-79.27%-30.6%-11.2%-1.41%
FCF Growth %-0%0.12%-0.38%
FCF per Share-144.14-143.66-222.53-18.61
FCF Conversion (FCF/Net Income)0.90x0.78x0.65x1.14x
Interest Paid0000
Taxes Paid0000

Key Ratios

Metric2021202220232024
Return on Equity (ROE)---387.34%-208.27%
Return on Invested Capital (ROIC)---278.96%-445079.83%
Gross Margin100%100%100%100%
Net Margin-8126.98%-3760.69%-1644.87%-119.57%
Debt / Equity--0.30x0.10x
Interest Coverage-137.70x-37.53x-44.42x-903383.22x
FCF Conversion0.90x0.78x0.65x1.14x
Revenue Growth-158.18%141.55%993.29%

Frequently Asked Questions

Growth & Financials

Azitra, Inc. (AZTR) reported $7.5M in revenue for fiscal year 2024. This represents a 6718% increase from $0.1M in 2021.

Azitra, Inc. (AZTR) grew revenue by 993.3% over the past year. This is strong growth.

Azitra, Inc. (AZTR) reported a net loss of $11.1M for fiscal year 2024.

Dividend & Returns

Azitra, Inc. (AZTR) has a return on equity (ROE) of -208.3%. Negative ROE indicates the company is unprofitable.

Azitra, Inc. (AZTR) had negative free cash flow of $11.1M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.